Therapeutic treatment of many disease models, including cancer, requires multiple dosing of therapeutic agents, which often results in harmful side effects such as myelosuppression and cardio- and neurotoxicity due to repeated systemic exposure [9,15,16]. Furthermore, disease models that result in tissue injury, often require scaffolding materials to support tissue regeneration [17,18].  The development of implantable extended drug release systems is necessary to enable sustained local therapeutic delivery, circumventing multiple dosing of drugs while also minimizing exposure to normal tissue and cells.  Additionally, scaffolds provide matrix support for cellular implantation and growth for tissue regeneration applications.  Hydrogels have been extensively investigated as implantable scaffolds for drug delivery due to their unique properties.  Hydrogels are water-soluble polymers that form porous three-dimensional cross-linked networks which enable drug loading [19].  Hydrogels are generally biocompatible and biodegradable, making them good candidates for in vivo application.  Their degradation can be engineered to be triggered by pH, temperature, or enzymatic activity, allowing for controlled release based on environmental conditions [20].  Additionally, peptides can be designed to self-assemble into hydrogels, by designing sequences of polar and non-polar tandem repeats and have shown promise in tissue engineering applications.  Therefore, our lab is developing self-assembling polymeric and peptide scaffolds for controlled release of multiple therapeutics, including drugs, siRNAs, pDNAs, growth factors, and proteins for tissue engineering following injury and cancer therapy (Fig. 3).